- Extensive global pharmaceutical leadership experience in
clinical development, operations, and medical affairs
- Focused psychiatry practice expert in PTSD, Affective
Disorders and Schizophrenia
- Proven track record in research as an investigator and
academic grant-funded researcher
- Visiting Scholar at Stanford University, Center for Precision Mental
Health and Wellness
- Former roles at Boehringer Ingelheim and Pendulum
Therapeutics
RADNOR,
Pa., Dec. 5, 2022 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals",
the "Company"), a clinical-stage central nervous system (CNS)
biopharmaceutical company, today announced the appointment of
Carrie M. Carretta, PhD, APN-BC,
AHN-BC, PMHNP as Senior Vice President, Clinical Development and
Medical Affairs. She will lead the Company's clinical
development program and provide medical oversight across all
indications. Dr. Carretta will report to the Chief Executive
Officer and Director.
NRx Pharmaceuticals Announces the
Appointment of Carrie M. Carretta,
PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical
Development and Medical Affairs
"The NRx team is excited to have attracted a clinician with deep
experience as an investigator. Dr. Carretta's wealth of
knowledge will help drive our mission to develop a first-in-class
lifesaving drug for suicidal depression and PTSD. She has
invaluable experience in both front-line care and corporate drug
development that will benefit both patients and shareholders.",
said Stephen Willard, Chief
Executive Officer, and Director, NRx Pharmaceuticals.
Dr. Carretta has extensive leadership experience in the
pharmaceutical industry, developing and executing strategies in
medical, clinical scientific and regulatory affairs as well as
hiring, developing, and managing diverse medical science and
clinical teams globally. She brings with her an extensive
network of key opinion leaders, health care providers and
researchers worldwide.
Dr. Carretta is the co-founder and managing partner at C&G
Holdings, LLC and most recently worked for Boehringer Ingelheim
Pharmaceuticals as the Executive Director, Therapeutic Area Head
for Clinical Development and Medical Affairs leading the CNS and
Ophthalmology areas. Prior to this role, Dr. Carretta served as the
Vice President, Medical and Scientific Affairs at Pendulum
Therapeutics.
Prior leadership roles at Juul Labs included developing
infrastructure and strategies which supported the company's
consumer device and her work for Novartis contributed to medical
excellence for Cosentyx®, Ilaris®, Entresto® and
Kisquali®, with Bayer Pharmaceuticals for The
Betaconnect™ autoinjector used with Betaseron®, and with
Teva Pharmaceuticals for Adasuve®.
In addition to her experience in the pharmaceutical industry,
Dr. Carretta has acted as an investigator for numerous clinical
trials and has worked extensively in clinical practice both in
general and forensic psychiatry, and in academia as a funded
researcher.
Dr. Carretta holds a doctorate degree in Nursing from
Vanderbilt University and both master's
and bachelor's degrees in Nursing from Rutgers, The State University of New Jersey.
She is nationally board certified as an APN-BC, AHN-BC & PMHNP.
Dr. Carretta is a current visiting scholar at Stanford University, Center for Precision Mental
Health and Wellness.
About NRx
Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics for the treatment of central
nervous system disorders, specifically suicidal depression and
post-traumatic stress disorder (PTSD). The company's lead program
NRX-101, an oral, fixed-dose combination of D-cycloserine and
lurasidone, targets the brain's NMDA receptor and is being
investigated in a Phase 3 trial under a Food and Drug
Administration ("FDA") Special Protocol Agreement and Breakthrough
Therapy Designation in patients with bipolar depression and acute
suicidal ideation, an indication for which the only approved
treatment is electroshock therapy. NRx Pharmaceuticals has
also initiated a Phase 2b clinical
trial in patients with Sub-Acute Suicidality, potentially a
substantially broader indication. The Breakthrough Therapy
Designation and Special Protocol Agreement were awarded by the FDA
based on the Company's prior STABIL-B trial that demonstrated
substantial improvement over available therapy in reducing
depression and suicidality compared to placebo when patients were
treated with NRX-101 after a single dose of ketamine.
Cautionary Note Regarding
Forward-Looking Statements
This announcement of NRx Pharmaceuticals, Inc. includes
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995, which may include, but are not limited to, statements
regarding our financial outlook, product development, business
prospects, and market and industry trends and conditions, as well
as the Company's strategies, plans, objectives, and goals. These
forward-looking statements are based on current beliefs,
expectations, estimates, forecasts, and projections of, as well as
assumptions made by, and information currently available to, the
Company's management.
The Company assumes no obligation to revise any forward-looking
statement, whether as a result of new information, future events or
otherwise. Accordingly, you should not place reliance on any
forward-looking statement, and all forward-looking statements are
herein qualified by reference to the cautionary statements set
forth above.
CORPORATE CONTACT
Molly Cogan
Sr. Director, Global Communications
mcogan@nrxpharma.com
INVESTOR RELATIONS
Suzanne Messere
Investor
Relations
suzanne.messere@sternir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-the-appointment-of-carrie-m-carretta-phd-apn-bc-ahn-bc-pmhnp-senior-vice-president-of-clinical-development-and-medical-affairs-301694310.html
SOURCE NRx Pharmaceuticals, Inc.